Gyre Therapeutics (GYRE) Non Operating Income (2010 - 2022)
Gyre Therapeutics (GYRE) posted quarterly Non Operating Income of $167000.0 for Q4 2022, up 4075.0% year-over-year from $4000.0 in Q4 2021, and down 40.99% quarter-over-quarter from $283000.0 in Q3 2022.
Gyre Therapeutics (GYRE) Non Operating Income (2010 - 2022) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Non Operating Income for 12 consecutive years, with $167000.0 the latest figure, recorded in Q4 2022.
- In Q4 2022, Non Operating Income rose 4075.0% year-over-year to $167000.0; the TTM figure through Dec 2022 stood at $537000.0 (up 1276.92% YoY), while the FY2022 annual figure was $537000.0, up 1276.92% from the prior year.
- Non Operating Income retreated to $167000.0 in Q4 2022 per GYRE's latest filing, from $283000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $690000.0 in Q4 2018 and bottomed at $2000.0 in Q1 2022.
- Historically, Non Operating Income has averaged $273450.0 across 5 years, with a median of $225000.0 in 2022.
- Annual changes were most pronounced in 2021 — Non Operating Income plunged 94.91% — and 2022, when it surged 4075.0%.
- Gyre Therapeutics' Non Operating Income stood at $690000.0 in 2018, then tumbled by 44.64% to $382000.0 in 2019, then sank by 93.46% to $25000.0 in 2020, then tumbled by 84.0% to $4000.0 in 2021, then soared by 4075.0% to $167000.0 in 2022.
- Business Quant data shows GYRE's Non Operating Income at $167000.0 in Q4 2022, $283000.0 in Q3 2022, and $85000.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 167,000.00 |
| Sep 30, 2022 | 283,000.00 |
| Jun 30, 2022 | 85,000.00 |
| Mar 31, 2022 | 2,000.00 |
| Dec 31, 2021 | 4,000.00 |
| Sep 30, 2021 | 7,000.00 |
| Jun 30, 2021 | 11,000.00 |
| Mar 31, 2021 | 17,000.00 |
| Dec 31, 2020 | 25,000.00 |
| Sep 30, 2020 | 74,000.00 |
| Jun 30, 2020 | 128,000.00 |
| Mar 31, 2020 | 334,000.00 |
| Dec 31, 2019 | 382,000.00 |
| Sep 30, 2019 | 489,000.00 |
| Jun 30, 2019 | 601,000.00 |
| Mar 31, 2019 | 631,000.00 |
| Dec 31, 2018 | 690,000.00 |
| Sep 30, 2018 | 652,000.00 |
| Jun 30, 2018 | 602,000.00 |
| Mar 31, 2018 | 285,000.00 |